The contribution of the mouse in hazard identification studies

Toxicologic Pathology

Volumn 24, Issue 6, 1996, Pages 726-731

  Maronpot, R R ^a   Boorman, G A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

animal models; cancer bioassays; chronic toxicity; mechanisms of carcinogenicity; mouse liver tumors; National Toxicology Program; pharmaceuticals; species specific response

Indexed keywords

ANIMAL MODEL; CANCER RISK; CHEMICAL CARCINOGENESIS; LIVER TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SPECIES DIFFERENCE;

EID: 0030476707     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339602400611     Document Type: Review

References (17)

1. Alden CL, Smith PF, Piper CE. and Brcj L (1996). Commentary: A critical appraisal of the value of the mouse cancer bioassay in safety assessment. Toxicol. Pathol. 24: 000-000.
2. Boorman GA, Hailey R, Grumbein S, Chou BJ, Herbert RA, Goehl T, Mellick PW, Roycroft JH, Haseman JK, and Sills R (1994). Toxicology and carcinogenesis studies of ozone and ozone 4-(N-nitroromethylamino)-1-(3-pyridyl)-l-butanone in Fischer-344/N rats. Toxicol. Pathol. 22: 545-554.
3. Haseman JK and Huff JE (1987). Species correlation in long-term carcinogenicity. Cancers Lett. 37. 125-132.
4. Huff J (1993). Chemicals and cancer in humans: First evidence in experimental animals Environ. Health Perspect. 100: 201-210.
5. Huff J, Cirvello J, Haseman J, and Bucher J (1991). Chemicals associated with site-specific neoplasia in 1394 long-term carcinogenesis experiments in laboratory rodents. Environ. Health Perspect. 93: 247-270.
6. Klein-Szanto AJP, Conti CJ, and Aldaz CM (1991). Skin and oral mucosa. In: Handbook of Toxicologic Pathology, WM Haschek and CG Rousseaux (eds). Academic Press, New York, pp. 165-193.
7. Kolaja KL, Stevenson DE, Walborg EF, and Kahunig JE (1996). Reversibility of promoter induced hepatic focal preneoplastic lesion growth in male B6C3F1 mice. The Toxicologist 30: 162.
8. Lai DY, Baetcke KP, Vu VT, Cotruvo JA, and Eustis SL (1994). Evaluation of reduced protocols for carcinogenicity testing of chemicals: Report of a joint EPA/NIEHS workshop. Reg. Toxicol. Pharmacol. 19: 183-201.
9. Malarkey DE, Devereux TR, Dinse GE, Mann PC, and Maronpot RR (1995). Hepatocarcinogenicity of chlordane in B6C3F1 and B6D2F1 male mice: Evidence for regression in B6C3F1 mice and carcinogenesis independent of ras proto-oncogene activation. Carcinogenesis 16: 2617-2625.
10. Maronpot RR, Haseman JK, Boorman GA, Eustis SE, Rao GN, and Huff JE (1987). Liver lesions in B6C3F1 mice: The National Toxicology Program, experience and position. Arch. Toxicol. Suppl. 10: 10-26.
11. Melnick RL, and Kohn MC (1995). Mechanistic data indicate that 1,3-butadiene is a human carcinogen. Carcinogenesis 16. 157-163.
12. Newberne PM (1983). Editorial. How relevant are mice hepatomas to human risk? Toxicol. Pathol 2: 113-114.
13. Page NP (1977). Concepts of a bioassay program in environmental carcinogenesis. In: Environmental Cancer, HF Kraybill and M Mehlman (eds). Wiley and Sons, New York, pp. 87-171.
14. Purchase IFH (1980). Inter-species comparisons of carcinogenicity. Brit. J. Cancer 41: 454-468.
15. Sills RC, Hong HL. Greenwell A, Herbert RA, Boorman GA, and Devereux TR (1995). Increased frequency of K-ras mutations in lung neoplasms from female B6C3F1 mice exposed to ozone for 24 or 30 months. Carcinogenesis 16: 1623-1628.
16. Swenberg JA, Dietrich DR, McClam RM, and Cohen SM (1992). Species-specific mechanisms of carcinogenesis. In: Mechanisms of Carcinogenesis in Risk Identification, H Vanio, PN Magee, DB McGregor, and AJ McMichael (eds). International Agency for Research on Cancer, Lyon, pp. 477-500.
17. von Wittenau MS and Estes PC (1983). The redundancy of mouse carcinogenicity bioassays. Fund. Appl. Toxicol. 3: 631-639.